Kiora Pharmaceuticals is focused on developing innovative therapeutics for the treatment of orphan retinal diseases, particularly those that lead to severe vision loss. One of their key technologies is KIO-301, a molecular photoswitch designed to restore vision in patients suffering from inherited retinal diseases such as retinitis pigmentosa, choroideremia, and Stargardt disease. This therapy specifically targets retinal ganglion cells (RGCs), which remain viable even when photoreceptors (rods and cones) degenerate. By converting RGCs into light-sensing cells, KIO-301 allows these neurons to bypass the damaged photoreceptors and directly signal the brain, thereby restoring some degree of visual function.

KIO-301 operates by changing its molecular structure in response to light. In the absence of light, the photoswitch remains in an "off" position, but when exposed to light, it shifts to an "on" position. This transformation enables KIO-301 to block ion channels within the RGCs, activating them to transmit visual signals to the visual cortex of the brain. This innovative approach not only highlights the potential of molecular photoswitches in treating retinal diseases but also underscores Kiora Pharmaceuticals' commitment to addressing high unmet needs in ocular health.

United States

Kiora Pharmaceuticals, Inc. (Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need.

Kiora Pharmaceuticals

Company Details